bluuebunny/crossref_metadata_2025 huggingface dataset:
637-P: The Impact of the Lockdown on Romanian Patients with Type 1 Diabetes and Basedow-Graves’ Disease
Authors: GHERBON ADRIANA , FRANDES MIRELA , TIMAR ROMULUS
Published: May 2022

Introduction: The lockdown imposed in Romania to limit the spread of COVID-infection has led to socio-psychological changes, especially stress affecting the endocrine system.

Objectives: Monitoring the impact of the lockdown imposed in Romania on patients with type 1 diabetes (DM 1) and compensated Basedow-Graves’ disease (BGD) , in treatment with antithyroid drugs (AD) .

Material and Method: This retrospective observational study included 151 patients with DM 1 and BGD and was based on an original questionnaire published online with questions about blood glucose, HbA1c, and TSH, diabetologist and endocrinologist contact, access to treatment, and factors influencing the glycemic control.

Results: We observed that 71.52% reported that they were afraid to go to the hospital when their general condition was altered (p <0.001) , and 80.13% stated that the stress increased during the restrictions (p <0.001) . A percent of 68.87% felt overwhelmed by the multitude of information about their disease, which they had to manage on their own (p˂0.001) . However, 67.54% of patients stated that they were able to contact the diabetologist and endocrinologist more often, via telemedicine (p˂0.001) and only 37.74% agreed that they did not encounter difficulties in managing type 1 diabetes during the pandemic, compared to 25.16% who had difficulties. Also, 33.77% of patients had decompensations of BGD, although initially the TSH value was within normal limits under treatment with AD.

Conclusions: Stress and anxiety were among the main causes that led to increased blood sugar levels and decompensation of BGD, suggesting that the psychological impact of the pandemic could bring long-term complications. References 1. Aragona M et al. Type 1 diabetes and COVID-19: The"lockdown effect." Diabetes Res Clin Pract. 2020 Dec;170:108468. 2. Gherbon A et al. Transient hyperthyroidism following the ingestion of complementary medications containing kelp seaweed: A case-report. Medicine. 20Sep;98 (37) .

Disclosure

A.Gherbon: None. M.Frandes: None. R.Timar: None.
649-P: Real-Time Continuous Glucose Monitoring in the Hospital Identifies and Prompts Treatment for Hypoglycemia
Authors: BAKER MATT , WELSH JOHN
Published: May 2022

Reliance on point-of-care (POC) blood glucose measurements for inpatient diabetes management can result in long between-measurement intervals, which contribute to undetected and untreated dysglycemia. The G6 real-time continuous glucose monitoring (RT-CGM) system (Dexcom) allows for remote monitoring. In the hospital, this may reduce the need for close interactions and infectious disease transmission between patients and hospital staff. A man in his mid-60s was admitted to a non-intensive care unit in an acute care facility with a diagnosis of COVID-19. His preadmission type 2 diabetes was managed with twice-daily intermediate-acting insulin and prandial rapid-acting insulin; steroids and POC glucose testing (prandial and bedtime with a FreeStyle Precision Pro meter [Abbott]) were added to this regimen. A G6 was placed on the abdomen and was set to alert the staff to glucose values ≤85 mg/dL or predicted to be <55 mg/dL within 20 minutes. Two hypoglycemic events occurred which triggered three G6 alerts (Figure) . The G6 alerts prompted ad hoc POC measurements that confirmed the hypoglycemic events, prompted appropriate interventions, and documented the patient’s return to euglycemia. All seven G6 readings were within 20 mg/dL or 20% of POC values ≤100 or >100 mg/dL, respectively. Inpatient RT-CGM use can detect existing or impending hypoglycemia and assist in diabetes management.

Disclosure

M.Baker: Other Relationship; Dexcom, Inc. J.Welsh: Employee; Dexcom, Inc.

Funding

Dexcom, Inc.
677-P: Impact of Third Dose COVID-Vaccination on Glycaemic Control in Individuals with Type 1 Diabetes Using Flash Glucose Monitoring
Authors: PIERALICE SILVIA , MONTE LAVINIA , DEFEUDIS GIUSEPPE , TABACCO GAIA , NAPOLI NICOLA , POZZILLI PAOLO
Published: May 2022

Background: Coronavirus (COVID-19) disease portends a poor prognosis in patients with type 1 diabetes (T1D) . As a consequence, the booster dose of Covid-vaccination should be prioritized in these patients. Nonetheless, concerns exist about vaccine-induced dysglycemia.

Objectives: Aim of this study was to assess the short-term effects of booster dose of Covid-vaccination on glycaemic control assessed by flash glucose monitoring (FGM) in people with T1D.

Methods: In this observational cross-sectional study we investigated changes in daily insulin requirement (IR) and glycaemic control between 7 days before and 7 days after the third dose of vaccination with BioNTech Pfizer among 30 individuals with T1D on multiple daily insulin injections wearing a flash glucose monitoring (FGM) device. The following parameters of glycaemic variability were analysed: mean glucose, time in range (TIR) , time above range (TAR) , time below range (TBR) and coefficient of variation (CV) .

Results: No significant differences were found for mean glycemia, TIR, TAR and TBR over the course of the vaccination from 7 days prior to receiving the third-dose vaccination until 7 days after. Nonetheless, CV and IR were significantly higher (CV, p-value = 0.001; IR, p-value = 0.05) in the week after the vaccination compared to the week earlier. The median value of CV was 35.5% [33-37] before and 36.9% [34-39] after the booster dose, whereas the median value of IR changed from 0.55 UI/Kg/day to 0.61 UI/Kg/day.

Conclusions: Our study suggests that the booster dose of Covid-vaccination impact on glycaemic variability and insulin requirement in people with T1D, probably due to the pro-inflammatory cytokines and immune responses. While this observation should be investigated in larger studies, potential glycaemic aberrations in response to Covid-immunization should be considered by health care professionals and glucose monitoring intensified within the days around the vaccination.

Disclosure

S.Pieralice: None. L.Monte: None. G.Defeudis: None. G.Tabacco: None. N.Napoli: Advisory Panel; Novo Nordisk, Consultant; Lilly Diabetes. P.Pozzilli: Advisory Panel; Dompé, Consultant; Abbott, Speaker’s Bureau; Dompé, Lilly Diabetes, Medtronic, Sanofi.
680-P: Effect of the FreeStyle Libre System on Diabetes Treatment for People with T2D: Results from a Retrospective Cohort Study Using Canadian Private Payer Claims Database
Authors: HARRIS STEWART B. , LEVRAT-GUILLEN FLEUR
Published: May 2022

Introduction: Therapeutic inertia is a major contributor to people with diabetes not achieving glycemic goals. We assessed for patients with T2D the impact of using the FreeStyle Libre system (FSL) vs. blood glucose monitoring (BGM) on treatment intensification.

Method: We carried out a matched retrospective cohort study using secondary private payer claims data including >30 million diabetes drug and device claims filled by over 850,000 patients with T2D >18 in Canada over 24 months. Each month, patients were classified by level of therapy progression: 1. No diabetes drug therapy; 2. Mono Oral Antihyperglycemic Agents (OHAs) ; 3. Dual OHAs; 4. Triple OHAs; 5. Quad or more OHAs; 6. Injectable GLP1-RA (±concomitant OHAs) ; 7. Basal insulin (±concomitant OHAs) ; 8. MDI insulin (±concomitant OHAs) .

Results: A total of 373,871 patients met the inclusion criteria. Across all treatment cohorts, the FSL treatment groups were found to have a statistically higher probability of treatment intensification relative to BGM:

Conclusion: Reimbursement of FSL for patients with T2D in Canada is associated with decreased time lag for glucose lowering therapy compared to those using BGM alone. These findings suggest that FSL data impact clinicians to facilitate earlier and more intensive therapy modifications and thus reduce treatment inertia.

Disclosure

S.B.Harris: Consultant; Abbott, AstraZeneca, Eli Lilly and Company, Novo Nordisk, Sanofi, Other Relationship; Abbott, AstraZeneca, Bayer Inc., Dexcom, Eli Lilly and Company, HLS Therapeutics, Janssen Pharmaceuticals, Inc., Novo Nordisk, Sanofi, Research Support; Applied Therapeutics Inc., AstraZeneca, Canadian Institutes of Health Research, Juvenile Diabetes Research Foundation (JDRF) , Novo Nordisk, Sanofi, The Lawson Foundation. F.Levrat-guillen: Employee; Abbott.

Funding

Funded by Abbott Diabetes Care
703-P: Significant Weight Reduction and Improvement in Glycemic Control among People with T2D after Participation in Diabefly Digital Therapeutics Program
Authors: VERMA RITIKA , KHADER MOHAMMED A. , MALDE FORUM , LATHIA TEJAL , TANNA SNEHAL R. , KOTHARI SNEHA , THAKKAR PIYA , THAKUR SANTOSH B. , GUNTUR SAIMALA , SINGAL ARBINDER K.
Published: May 2022

Background: Digital therapeutics platforms provide accessible and multidisciplinary care for the management of T2D. The current study explored the effectiveness of the Diabefly program for improving glycemic control in people with T2D.

Methods: Diabefly program provides a combination of mobile application, remote lifestyle coaching, live video consultations by experts (psychologist, physiotherapist and nutritionist) , and digital logging of parameters. The outcome of the study was to evaluate the change in HbA1c, fasting blood sugar (FBS) , postprandial blood sugar (PPBS) , weight, and body mass index (BMI) at the beginning and end of the program. All the outcomes were evaluated using paired t-test with P<0.considered as significant.

Results: A significant mean reduction in HbA1c levels by 1.69 ± 1.91% from a baseline of 8.66 ± 2.05% was observed (P<0.001) . Among all the participants, 93.02% (160/172) showed a reduction in their HbA1c, out of which 56.25% (90/160) showed a HbA1c reduction of more than 1%. Similarly, weight and BMI were also significantly reduced by 2.59 ± 3.31 kg and 0.92 ± 1.15 kg/m2 from a baseline of 75.94 ± 16.24 kg and 27.49 ± 4.71 kg/m2 respectively (P<0.0for both) . Among all the participants, 70.34% (121/172) reduced their weight, out of which 32.23% (39/121) showed a weight reduction of at least 5 kg. Among participants (n=42) with complete FBS and PPBS data, a significant mean reduction by 51.44 ± 58.87 mg/dL and 90.90 ± 78.96 mg/dL from a baseline of 164.87 ± 63.83 mg/dL and 227.95 ± 82.34 mg/dL was observed respectively (P<0.0for both) .

Conclusion: Effective glycemic control and significant weight reduction was achieved at the end of the program. Thus, Diabefly program can help in providing continuous support to implement lifestyle changes between quarterly doctor visits and greater usage of a remote lifestyle coaching can be a useful adjunct to doctor’s prescription for holistic management of diabetes.

Disclosure

R. Verma: Employee; Fitterfly Healthtech Pvt Ltd, Wellthy Therapeutics Pvt Ltd. M.A. Khader: Employee; Fitterfly HealthTech Pvt Ltd. T. Lathia: Advisory Panel; Abbott, AstraZeneca, Biocon, Boehringer Ingelheim International GmbH, Novartis Pharmaceuticals Corporation, Novo Nordisk, Sanofi. S. Guntur: Employee; Fitterfly Health Tech Pvt. Ltd. A.K. Singal: Other Relationship; Fitterfly Healthtech Pvt Ltd.
742-P: Antidrug Antibodies Do Not Impact Pharmacokinetics, Efficacy, and Safety of Tirzepatide: Analysis of Data from 7 Phase 3 Studies
Authors: CALDERON BORIS , MULLINS GARRETT R. , HODSDON MICHAEL , LI GRACE , ANGLIN GREG , URVA SHWETA , SCHNECK KAREN , BARDOS JENNIFER N. , MARTINS RICARDO F. , BROWN KATELYN
Published: May 2022

Tirzepatide (TZP) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon like peptide (GLP) -1 receptor agonist developed for the treatment of type 2 diabetes. Patients receiving TZP may develop an immune response to the 39 amino acid synthetic peptide. This study aimed to evaluate treatment emergent (TE) anti-drug antibodies (ADA) in TZP-treated participants across 7 Phase 3 trials and its potential effect on pharmacokinetics (PK) , efficacy, and safety. A multi-tiered immunogenicity testing strategy was used to detect and characterize ADA. ADA were characterized for their ability to cross react to native GIP (nGIP) and GLP-1 (nGLP-1) , neutralize TZP activity on GIP and GLP-1 receptors, and neutralize nGIP and nGLP-1. ADA were assessed at baseline and throughout the course of the study up to week 40 (SURPASS 1, 2, and 5) or week 52 (SURPASS 3, 4, Japan-mono, and Japan-combo) . Among all ADA-evaluable patients across the Phase 3 trials (N=5025) , TE ADA developed in 51.1% of patients treated with TZP, and the proportions were similar across the 3 TZP dose groups (5, 10, and 15 mg) . At baseline, 7.0% of patients had pre-existing ADA. Maximum ADA titers ranged from 1:20 to 1: 81920 (median 1:160) among TE ADA+ patients. Neutralizing antibodies (NAb) against TZP activity on GIP and GLP-1 receptors were observed in 1.9% and 2.1% of the TE ADA+ patients, respectively. Less than 1.0% of TZP-treated TE ADA+ patients had cross-reactive NAb against nGIP or nGLP-1. TE ADA status, ADA titer, and NAb had no discernible impact on PK profile nor HbA1c effects of TZP. The percentage of TE ADA+ and TE ADA- patients with hypersensitivity reactions was similar. A higher proportion of TE ADA+ patients reported injection site reactions, of which all were nonserious and non-severe, and the vast majority occurred and/or resolved irrespective of TE ADA status or titer level.Overall, immunogenicity was not associated with any impact on TZP PK, efficacy, or safety.

Disclosure

B. Calderon: Employee; Eli Lilly and Company. G.R. Mullins: Employee; Eli Lilly and Company. M. Hodsdon: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company. G. Li: Employee; Eli Lilly and Company. G. Anglin: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company. S. Urva: Employee; Eli Lilly and Company. K. Schneck: Employee; Eli Lilly and Company. J.N. Bardos: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company. R.F. Martins: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company. K. Brown: Employee; Eli Lilly and Company.

Funding

Funded by Eli Lilly and Company.
746-P: The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES) : Final 24-Month Primary Endpoint Analysis
Authors: GIORGINO FRANCESCO , GUERCI BRUNO , GARCIA-PEREZ LUIS-EMILIO , FUECHTENBUSCH MARTIN , LEBREC JEREMIE , ORSINI FEDERICI MARCO , DIB ANNE , HEITMANN ELKE , YU MARIA , BOYE KRISTINA
Published: May 2022

TROPHIES was a 24-month, prospective, non-comparative, observational study in adult patients with T2D initiating their first injectable glucose-lowering treatment with once-weekly dulaglutide (DU; N=1,014) or once-daily liraglutide (LIRA; N=991) in France, Germany, and Italy. Primary objective: to assess the time patients remained on their first GLP-1 RA without a significant treatment change due to treatment- or diabetes-related factors. Kaplan-Meier (KM) probability (95% CI) of no significant treatment change at 24 months was 0.71 (0.68-0.74) and 0.53 (0.49-0.56) in the DU and LIRA cohorts, respectively (Figure) . Two-hundred and eighty-six (28.2%) and 448 (45.2%) patients receiving DU and LIRA, respectively, had a significant treatment change. The main driver of treatment change in the DU and LIRA cohorts was intensification with an add-on therapy (insulin or OAD) and intensification with dose increase of GLP-1 RA, respectively. KM probability (95% CI) of GLP-1 RA persistence at 24 months was high in both cohorts: DU 0.82 (0.80-0.85) ; LIRA 0.75 (0.72-0.78) .

In summary, the probabilities of no significant treatment change over 24 months were estimated as higher in the DU cohort than in the LIRA cohort in this non-comparative analysis, with good persistence in both cohorts.

Disclosure

F. Giorgino: Advisory Panel; AstraZeneca, Boehringer Ingelheim International GmbH, Novo Nordisk. Consultant; Lilly Diabetes, Sanofi. Research Support; Lilly Diabetes, Roche Diabetes Care, Takeda Pharmaceutical Company Limited. B. Guerci: Advisory Panel; Amgen Inc., Medtronic. Board Member; Abbott Diagnostics, AstraZeneca, Bayer AG, Eli Lilly and Company, Novartis Pharmaceuticals Corporation. Consultant; Boehringer Ingelheim International GmbH, Intercept Pharmaceuticals, Inc., Novo Nordisk. L. Garcia-Perez: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company. M. Fuechtenbusch: Advisory Panel; Berlin-Chemie AG. Consultant; Boehringer Ingelheim International GmbH, Eli Lilly and Company, Merck Sharp & Dohme Corp. Speaker's Bureau; AstraZeneca, Novo Nordisk. J. Lebrec: Consultant; Eli Lilly and Company. M. Orsini Federici: Employee; Eli Lilly and Company. A. Dib: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company. E. Heitmann: None. M. Yu: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company. K. Boye: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company.
77-OR: Native LDL Upregulate the NLRP3 Inflammasome in Human Adipose Tissue: A Mechanism for Higher Risk for Type 2 Diabetes in Subjects with HyperapoB
Authors: BISSONNETTE SIMON , LAMANTIA VALÉRIE , CYR YANNICK , DEVAUX MARIE , RABASA-LHORET RÉMI , CHRETIEN MICHEL , SALEH MAYA , FARAJ MAY
Published: May 2022

Background and Hypothesis: Elevated plasma apoB-lipoproteins (hyperapoB, mostly LDL) predicts the incidence of type 2 diabetes (T2D) and its risk factors including systemic activation of the interleukin-1 system (measured as plasma IL-1 receptor antagonist, IL-1Ra) . Moreover, native LDL induce white adipose tissue (WAT) dysfunction. Underlying mechanisms for these findings remain unclear. Activation of WAT NLRP3 inflammasome and secretion of IL-1β promotes WAT dysfunction and related risk factors for T2D. We hypothesized that native LDL upregulate WAT NLRP3 inflammasome/IL-1β pathway.

Methods: This data represents baseline analysis of a 3-month clinical trial with omega-3 fatty acid supplementation in nondiabetic men (N=13) and women (N=27) . We assessed insulin secretion and sensitivity by Botnia clamps, postprandial fat metabolism after a high-fat-meal (68% fat) , and priming and/or activation of NLRP3 inflammasome in subject hip WAT biopsies ex vivo using native LDL, lipopolysaccharides (LPS) (priming control) and/or ATP (activation control) .

Results: Incubation of WAT with native LDL (1.2 g apoB/L) increased IL-1β secretion in ATP- but not LPS-treated WAT. Subjects with higher than median plasma apoB (1.23±0.15 g/L) had higher WAT IL-1β-secretion than those with lower apoB, using multiple combination of LDL, LPS and/or ATP, independent of adiposity, macronutrient intake or plasma lipids. WAT NLRP3 mRNA expression and IL-1β secretion correlated positively with hyperinsulinemia, insulin resistance, postprandial hypertriglyceridemia and hyperchylomicronemia and plasma IL-1Ra. Adjusting for sex and WAT IL-1β-secretion or sex and plasma IL-1Ra eliminated the association of plasma apoB with these risk factors (except hypertriglyceridemia) .

Conclusion: Native LDL are priming signals of WAT NLRP3 inflammasome, which may explain higher risk for T2D in subjects with hyperapoB. ClinicalTrials.gov (NCT04496154) .

Disclosure

S.Bissonnette: None. V.Lamantia: None. Y.Cyr: None. M.Devaux: None. R.Rabasa-lhoret: Consultant; HLS Therapeutics Inc., Pfizer Inc., Other Relationship; Abbott Diabetes, AstraZeneca, Boehringer Ingelheim International GmbH, Dexcom, Inc., Eli Lilly and Company, Insulet Corporation, Janssen Pharmaceuticals, Inc., Medtronic, Merck & Co., Inc., Novo Nordisk Canada Inc., Sanofi, Vertex Pharmaceuticals Incorporated, Research Support; Canadian Institutes of Health Research, Cystic Fibrosis Canada, Diabetes Canada, Fondation Francophone pour la Recherche en Diabète (FFRD) , JDRF, National Institutes of Health, Société Francophone du Diabète (SFD) , Speaker's Bureau; Canadian Medical & Surgical Knowledge Translation Research Group (CMS) , CPD Network, Tandem Diabetes Care, Inc. M.Chretien: None. M.Saleh: None. M.Faraj: None.

Funding

Canadian Institutes of Health Research (CIHR) (FRN# 123409)
785-P: Comparison of Six Months Experience on Hybrid Closed Loop MiniMed 670G System and Advanced Hybrid Closed Loop MiniMed 780G System Using a Structured Initiation Protocol in Children and Adolescents with Type 1 Diabetes
Authors: PETROVSKI GORAN , CAMPBELL JUDITH , ALKHALAF FAWZIYA , HUSSAIN KHALID
Published: May 2022

Background: The objective of this study was to evaluate glycemic outcomes using a structured initiation protocol for Hybrid Closed Loop (HCL) MiniMed 670G and Advanced Hybrid Closed Loop (AHCL) Minimed 780G system in children and adolescents with Type 1 Diabetes (T1D) previously treated with Multiple Daily Injections.

Methods: The data from two separate (HCL and AHCL system) investigations were analyzed in individuals (aged 7-18 years) with T1D on MDI therapy, both followed a structured initiation protocol. Time in Ranges, HbA1c and system characteristics were analyzed between two systems at 3 and 6 months of Automated Insulin Delivery (AID) .

Results: 30 children (age 10.24 ± 2.6 years, HbA1c 8.2±1.4% (66±15.3 mmol/mol)) with HCL system and 34 children (12.5 ± 3.7 years, 8.6±1.7% (70±18.6 mmol/mol)) with AHCL system completed the planned 12 weeks of AID. TIR (70-180mg/dl) of 73.4±8.9% with HCL and 78.2±4.3% with AHCL (p=0.01) was achieved at 6 months of AID. No episodes of severe hypoglycemia or DKA were reported using both systems.

Conclusion: Individuals using AHCL MiniMed 780G system had more stringent system settings, spent more time in AID with less exits, which possibly lead to further improvements of glycemic control compared to HCL MiniMed 670G system using the same structured protocol.

Disclosure

G.Petrovski: None. J.Campbell: Advisory Panel; Medtronic. F.Alkhalaf: None. K.Hussain: None.
792-P: Evaluation of Long-Term Glycemic Outcomes by Ethnicity in Adults with Type 1 Diabetes Using Control-IQ Technology
Authors: GRAHAM RISHI , SINGH HARSIMRAN , MUELLER LARS , MANNING MICHELLE L. , ALENCAR GABRIEL , WHITE KIRSTIN N. , WHEATCROFT ALEX , CARMELO KAREN , KATCHALSKI RAVID , ARONOFFSPENCER ELIAH S. , PINSKER JORDAN E. , HABIF STEPHANIE
Published: May 2022

Despite increasing prevalence of T1D in ethnic minorities, they remain underrepresented in research studies evaluating diabetes technologies. Experiences of diverse cohorts are essential to assessing acceptability of diabetes devices. The Control-IQ Observational (CLIO) Study is an ongoing prospective, real-world evaluation of the Tandem Diabetes Care t:slim X2 insulin pump with Control-IQ technology in diverse people with T1D. We evaluated glycemic metrics from adults completing the 12-month CLIO study. Participants with ≥75% overall CGM use during this time were included in the analysis. Outcomes were analyzed using a Wilcoxon test. Sample included 1,045 adults (921 Whites, 74 Hispanics, 34 Blacks, 16 Asians) with Black participants reporting the highest baseline HbA1c (median=8% [IQR=7-8.6)) . Glucose Management Indicator (GMI) at study end reflected glycemic improvements for participants with Blacks showing a clinically relevant 0.7% overall reduction (7.3% [6.9-7.6]) (p<0.001) (Figure 1) . Overall, sensor time in range (TIR) at 12 months ranged from 64.9% [56.8-70.5] for Black participants to 72.6% [62.8-80.8] for the White cohort. These findings confirm long-term successful use of Control-IQ technology across diverse ethnicities. Further evaluation of glycemic disparities is recommended to help inform patient support systems.

Disclosure

R.Graham: Research Support; Tandem Diabetes Care, Inc. E.S.Aronoffspencer: Research Support; Tandem Diabetes Care, Inc. J.E.Pinsker: Employee; Tandem Diabetes Care, Inc., Stock/Shareholder; Tandem Diabetes Care, Inc. S.Habif: Employee; Tandem Diabetes Care, Inc. H.Singh: Employee; Tandem Diabetes Care, Inc. L.Mueller: Employee; Tandem Diabetes Care, Inc., Research Support; Dexcom, Inc., Stock/Shareholder; Tandem Diabetes Care, Inc. M.L.Manning: Employee; Tandem Diabetes Care, Inc. G.Alencar: Employee; Tandem Diabetes Care, Inc. K.N.White: Employee; Tandem Diabetes Care, Inc. A.Wheatcroft: Employee; Tandem Diabetes Care, Inc. K.Carmelo: None. R.Katchalski: Employee; Tandem Diabetes Care, Inc.

Funding

Tandem Diabetes Care
800-P: Real-World Use of Do-It-Yourself Artificial Pancreas Systems in Adults with Type 1 Diabetes
Authors: AMUEDO SANDRA , ANTEQUERA MARÍA , AZRIEL SHARONA
Published: May 2022

Background and Aims: Members of the diabetes community have started developing their own Do-It-Yourself Artificial Pancreas Systems (DIY APS) , also known as Open-Source Automated Insulin Delivery (AID) Systems and use the online hashtag “#WeAreNotWaiting” to promote the development of it. DIY APS systems inclued OpenAPS, Loop and AndroidAPS. The aim of the study was to evaluate retrospectively glycemic outcomes with the use of DIY APS in adults with T1D.

Methods: Subjects with T1D started using open-source AID systems (AndroidAPS with Insight insulin pump and Dexcom G6 or FreeStyle Libre 2 CGM and Loop with Minimed Paradigm and Dexcom G6) . Glycemic outcomes at baseline on open-loop and after 12 months on DIY APS were compared including time in different glucose ranges, management indicator (GMI) , mean glucosa levels, glycemic variability and Patient Glycaemic Status (PGS) .

Results: Patients with T1D users open-source AID systems (22 AndroidAPS and 1 Loop) were included (age 38.4±years, 56.5% females, diabetes duration 20.8±10.6 years and capillary HbA1c 6.6±0.5%) . 18 patients previous insulin pump users with a use 3.5±4 years, 5 patients previously treated with multidose and CGM use 2.6±2.1 years. GMI decreased from 6,6±0.6% to 6±0.5% (p<0.001) . At 12 months, time in range (TIR) 70-180 mg/dL increased from 69.9±11.5% at baseline to 87.5±7.8% (p<0.001) , time in hyperglycemia >180 and >250 mg/dL were reduced from 23.5±11,5% to 9.6±7.5% and from 5.1% (2-9) to 0.6% (0-3) , respectively (p<0.001) and time in hypoglycemia <70 and <54 mg/dL decreased from 5±3.6% to 2.8±2.1% (p=0.006) and from 1.3±1.5% to 0.4±0.5% (p=0.014) . Improvements in glycemic variability from 35.7±6% to 30.3±6.2% (p=0.001) . At 12 months, PGS and sensor glucose were reduced from 54.4±36% to 23±19.6% and from 144.7±18.3% to 127±14% (p<0.001) .

Conclusions: Open-source AID systems is safe and improved outcomes glycemic after 12 months of use in a real-world clinical setting in adults with T1D.

Disclosure

S.Amuedo: None. M.Antequera: None. S.Azriel: None.
844-P: Jatupalathika Extract Acts via G-Protein-Coupled Receptors to Stimulate GLP-1 Secretion in STC-1 Cell Line
Authors: CHAICHANA CHARTCHAI , KHUMKHANA NANTA , WONGSHAYA PAKWUAN , DEEKUM WANJAN , PRAMYOTHIN PORNPOJ
Published: May 2022

One of the most important molecular targets for the prevention and treatment of diabetes is glucagon-like peptide-1 (GLP-1) , a molecule secreted by enteroendocrine L cells in the intestine. It has been reported that nutrients, as well as non-nutritional dietary factors, can activate GLP-1 secretion. Jatupalathika (JPT) is a traditional herbal formulation of four dried fruits: Terminalia bellirica (Gaertn.) Roxb., Terminalia chebula Retz., Terminalia arjuna (Roxb.) Wight & Arn., and Phyllanthus emblica Linn. JPT extracts have traditionally been used for their anti-oxidant, anti-aging, body fat depletion, and weight loss properties. However, its effects on glucose metabolism and GLP-1 are not known. Thus, we evaluated the antidiabetes potential of JPT aqueous extracts by assessing its ability to induce GLP-1 secretion in a mouse intestinal cell line (STC-1) . The MTT assay was used to assess the cytotoxicity, and the LUMINEX multiplex assays were used to assess GLP-1 hormone secretion. When compared to control, JPT extracts (125 µg/ml) increased GLP-1 secretion after 45-120 minutes of incubation without any effects on cell survival. The mechanism of action of GLP-1 secretion activity in cells was studied using real-time PCR. We discovered an increase in expression of six genes related to GLP-1 secretion: SLC5A1 (encoding SGLT1) , FFAR2 (encoding GPR43) , FFAR3 (encoding GPR41) , GPR119, GPBAR1, and CABP1. This finding demonstrated that JTP extract significantly increased GLP-1 hormone production via G-protein-coupled receptor activation, which also promotes Ca2+ release from the endoplasmic reticulum. Phytochemical profiling and molecular docking study revealed that Ellagic acid and Orientin are abundant metabolites with a favorable ability to bind the FFAR2/3 protein, acting as potential agents that aid in GLP-1 production. The findings showed that JPT might be useful in the prevention and treatment of diabetes. However, more research on in vivo effects is required.

Disclosure

C.Chaichana: None. N.Khumkhana: None. P.Wongshaya: None. W.Deekum: None. P.Pramyothin: Research Support; Novo Nordisk, Speaker's Bureau; AstraZeneca, Boehringer Ingelheim International GmbH, Novo Nordisk.
859-P: Effects of Ertugliflozin on Uric Acid and Gout-Related Outcomes: Post Hoc Analyses from VERTIS CV
Authors: SRIDHAR VIKAS S. , COSENTINO FRANCESCO , DAGOGO-JACK SAMUEL , PRATLEY RICHARD E. , FREDERICH ROBERT , ESSEX MARGARET N. , MALDONADO MARIO , LIU CHIH-CHIN , MANCUSO JAMES P. , CHERNEY DAVID
Published: May 2022

The effect of ertugliflozin (ERTU) on serum uric acid (SUA) and gout-related outcomes in VERTIS CV (NCT01986881) was investigated. Patients with T2D and ASCVD were randomized to ERTU 5 mg (n=2752) , 15 mg (n=2747) (doses pooled for analyses) , placebo (PBO; n=2747) . Changes in SUA and composite of gout onset or initiation of anti-gout medication were assessed. LSM changes from baseline in SUA (mg/dL [95% CI]) at week 260 were −0. (−0.25, −0.13) and 0. (−0.02, 0.15) in the ERTU and PBO groups, respectively, nominal P<0.0 (Fig. 1) . The HR (95% CI) for the composite of gout-related outcomes was 0.76 (0.580, 1.002) , nominal P=0.052 (Fig. 2) . Treatment with ERTU was associated with reductions from baseline in SUA and a non-significant reduction in gout-related outcome events compared with PBO.

Disclosure

V.S.Sridhar: None. D.Cherney: Other Relationship; AbbVie Inc., AstraZeneca, Bayer AG, Boehringer Ingelheim International GmbH, Janssen Research & Development, LLC, Lilly, Maze, BMS, CSL-Behring, Merck, Otsuka, Novartis and Novo-Nordisk , Mitsubishi Tanabe Pharma Corporation, Sanofi, Research Support; Boehringer Ingelheim-Lilly, Merck, Janssen, Sanofi, AstraZeneca and Novo-Nordisk. F.Cosentino: Advisory Panel; Merck Sharp & Dohme Corp., Pfizer Inc., Speaker's Bureau; AstraZeneca, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Lilly, Merck Sharp & Dohme Corp., Novo Nordisk. S.Dagogo-jack: Consultant; AstraZeneca, Bayer AG, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Inc., Medtronic, Merck & Co., Inc., Sanofi. R.E.Pratley: Other Relationship; Bayer AG, Corcept Therapeutics, Dexcom, Inc., Hanmi Pharm. Co., Ltd., Merck & Co., Inc., Metavention, Novo Nordisk, Pfizer Inc., Poxel SA, Sanofi, Scohia Pharma Inc., Sun Pharmaceutical Industries Ltd. R.Frederich: Employee; Pfizer Inc., Stock/Shareholder; Bristol-Myers Squibb Company, Pfizer Inc. M.N.Essex: Employee; Pfizer Inc., Stock/Shareholder; Pfizer Inc. M.Maldonado: Employee; Merck & Co., Inc. C.Liu: Employee; Merck & Co., Inc., Stock/Shareholder; Merck & Co., Inc. J.P.Mancuso: Employee; Pfizer Inc., Stock/Shareholder; Pfizer Inc.

Funding

The VERTIS CV study and this analysis were sponsored by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and Pfizer Inc., New York, NY, USA.
87-OR: Female Sexual Dysfunction and Type 2 Diabetes: Results from the Diabetes Prevention Program Outcomes Study (DPPOS)
Authors: GUPTA PRIYANKA , DOHERTY LINDSAY , TEMPROSA MARINELLA , WESSELLS HUNTER , POP-BUSUI RODICA , GADDE KISHORE M. , OWORA ARTHUR H. , SARMA ARUNA V. ,   DPP RESEARCH GROUP
Published: May 2022

Introduction and Objective: Female sexual dysfunction (FSD) has been reported to be more common in women with T2D. However, detailed risk profiles are lacking. We sought to determine the burden and correlates of FSD in a well characterized cohort of women with Prediabetes (PreD) and T2D enrolled in the DPPOS.

Methods: Between 1996-1999, 3,234 adults with PreD were randomized to intensive lifestyle intervention, masked metformin, or placebo in the DPP. In 2001, open-label metformin was continued for those originally randomized to it and modified lifestyle intervention offered to all. In 2016-2017, 1320 of 1464 participants completed the Female Sexual Function Index (FSFI) . 426 women were sexually active and included in the current report. FSD was defined as FSFI≥26.55. A backwards selection multivariable logistic regression model estimated odds of FSD for sociodemographic, clinical, and diabetes-related covariates significant in bivariate analysis.

Results: Overall, 185 (43%) women met the criteria for FSD. After adjustment for treatment arm, age and race, depression (defined by the Beck Depression inventory or antidepressant use) and weekly urinary incontinence were both associated with over a two-fold (OR=2.81, 95%CI=1.57, 5.02; and OR=2.14, 95%CI=1.31, 3.51) increase in odds of FSD, respectively. Women who reported hysterectomy were 1.95 times more likely (95%CI=1.07, 3.54) to report FSD. Mean study BMI was slightly protective for FSD (OR=0.93, 95%CI=0.89, 0.96) . Neither DPP treatment group nor any diabetes-related factors were associated with FSD.

Conclusions: FSD is highly prevalent in this population of women with PreD and T2D. Our findings suggest that FSD in this cohort is most strongly associated with depression. The lack of association between any measures of diabetes or glycemic control suggests that the sexual response in women is more likely to be affected by psychosocial aspects than by metabolic control or complications of diabetes.

Disclosure

P.Gupta: Consultant; Inspire . L.Doherty: None. M.Temprosa: None. H.Wessells: None. R.Pop-busui: Advisory Panel; Averitas Pharma, Inc., Boehringer Ingelheim International GmbH, Nevro Corp., Novo Nordisk, Reata Pharmaceuticals, Inc., Regenacy Pharmaceuticals, Inc. K.M.Gadde: Research Support; AstraZeneca, BioKier, Inc. A.H.Owora: None. A.V.Sarma: None. D.Research group: None.

Funding

National Institute of Diabetes and Digestive and Kidney Diseases (UDK048489, UDK048339, UDK048377, UDK048349, UDK048381, UDK048468, UDK048434, UDK048485, UDK048375, UDK048514, UDK048437, UDK048413, UDK048411, UDK048406, UDK048380, UDK048397, UDK048412, UDK048404, UDK048387, UDK048407, UDK048443, and UDK048400)
927-P: The Impact of Community Health Worker Interventions on A1C in People of Racial/Ethnic Minority Groups with Type 2 Diabetes: A Systematic Review and Meta-analysis
Authors: SHETTY RAJ , DECKARD AMBER , WAN WEN , NATHAN AVIVA , STAAB ERIN M. , RODRIGUEZ ALEX W. , GANDHI ASHISH , BAIG ARSHIYA A. , LAITEERAPONG NEDA
Published: May 2022

Objective: Communities of racial/ethnic minority groups experience a higher prevalence of type 2 diabetes (T2DM) with higher rates of diabetes-related complications compared to non-Hispanic Whites. Interventions that utilize community health workers (CHW) are often successful at improving glycemic control. This analysis aimed to examine the effectiveness of CHW interventions on glycemic control in people of racial/ethnic minority groups with T2DM.

Methods: A search of electronic databases (PubMed, Scopus, CINAHL, PsycInfo) to identify articles published between 1985 and 20was conducted using broad search terms for diabetes, race/ethnicity, and disparities. To further refine articles to those focusing on CHW-based randomized controlled trials, abstracts were searched for “community workers” and “promotores.” A random effects model was used to calculate the effect of CHW interventions on hemoglobin A1c (HbA1c) with future plans to analyze effects on other cardiovascular risk factors such as body mass index, blood pressure, and cholesterol.

Results: A total of 22 RCTs were identified, involving 4996 adults (26% Black, 50% Hispanic, 11% Asian, and 11% Pacific Islander) . CHW interventions among people of racial/ethnic minority groups was associated with a 0.44% (95% confidence interval: -0.56% to -0.31%; p<0.0001) reduction in HbA1c.

Conclusion: CHW interventions are an effective means to lower HbA1c among people of racial/ethnic minority groups with T2DM. This finding is important for future healthcare policies, which should work to emphasize culturally sensitive interventions for patients with T2DM while maintaining cost effectiveness through CHWs. Future research should examine the effectiveness of CHWs for diabetes prevention.

Disclosure

R.Shetty: None. A.Deckard: None. W.Wan: n/a. A.Nathan: None. E.M.Staab: None. A.W.Rodriguez: None. A.Gandhi: None. A.A.Baig: None. N.Laiteerapong: None.
937-P: Multicenter application of EFR (Endocrine Final Recommendation) Note Embedded in EMR Improves the Accuracy of Diabetes Discharge Regimen in Hospitalized Patients with Diabetes
Authors: LLOYD JACOB , ABDULWAHID TIBA , LEVIN JOEL , PINKHASOVA DIANA
Published: May 2022

Patients with diabetes who are hospitalized often have changes in diabetes treatment regimen during hospitalization. In the ReCoDED study done at our institution, it was found that discharge instructions provided by Endocrine teams were not always accurately translated into discharge recommendations by primary teams. To address this issue, we implemented a “diabetes discharge recommendations note” (EFR Note) which clearly specifies discharge instructions for primary teams, which we embedded in the institution’s EMR in January 2019. Preliminary data evaluating the efficacy of the EFR Note at our academic center showed significantly improved accuracy in the discharge regimen.

In this study, we investigated the patient data from two other centers, specifically inner-city community hospitals, from January to December 2021. We identified 40 patients through EMR for whom an EFR Note was utilized (EFR Group) and randomly selected 40 patients from the same centers for comparison (Control Group) . There were no significant differences in baseline characteristics between the two groups (All p values > 0.25)

Results: We find that the accuracy of diabetes regimens provided by primary teams at discharge was significantly higher when EFR Note was utilized, relative to control (88% vs. 60%; χ2 (1) = 6.46, p = 0.011) . The most common error was incorrect insulin type/dosing, accounting for 76% of all errors. Insulin dosing errors were similarly less prevalent in the EFR Group relative to control (8% vs. 33%; χ2 (1) = 6.33, p = 0.012) .

Conclusion: These results demonstrate that tools like EFR Note with specific instructions regarding discharge regimen can ameliorate deficiencies in discharge process. We plan to take steps to enhance awareness regarding the efficacy of EFR Note among endocrinology providers at multiple centers within our institution to facilitate a safer transition from inpatient to outpatient setting.

Disclosure

J.Lloyd: None. T.Abdulwahid: None. J.Levin: None. D.Pinkhasova: None.
94-LB: A Phase 1, Double-Blind, Placebo-Controlled Multiple Escalating Dose Study of RGT-075 Novel Small-Molecule Oral GLP-1 Receptor Agonist in Adults with Type 2 Diabetes
Authors: PIRNER MARK A. , LIN JING , LIU FENG , YAO LILI , ZETTLER MARJORIE E. , VALACER DAVID J.
Published: May 2022

Background: RGT-075 is a small-molecule oral GLP-1 receptor agonist (GLP1RA) in clinical development. RGT-075 (15-280 mg) was well-tolerated by healthy adults in a prior phase 1 single ascending dose study. Phase 1 multiple-ascending dose study of RGT-075 in adults with type 2 diabetes (T2DM) results are presented.

Methods: A Phase 1, randomized, double-blind, placebo-controlled, inpatient study planned multiple daily doses of RGT-075 or matching placebo (6 active/2 placebo per cohort) for up to 28 days in T2DM patients (baseline HbA1c 6-10.5% and concomitant metformin >500 mg/d) . An adaptive study design permitted dose and titration adjustments. Assessments included safety (primary) , PK, and exploratory efficacy changes in HbA1c, fasting plasma glucose (FPG) , continuous glucose monitoring time in range (CGM-TIR) , mixed-meal tolerance test MMTT, and body weight (BW) .

Results: Four Cohorts enrolled 36 patients (56%F/44%M; mean age 55yF/61yM) to receive ([Starting Dose]→[Titration Duration]→[Target Dose]) : Cohort 1 [60 mg][ no titration][60 mg]; Cohort 2 [30 mg][10 d][120 mg]; Cohort 3 [15 mg][20 d][180 mg]; Cohort 4 [15 mg][28 d][45 mg]. Adverse events (AEs) were reported by most subjects (100% C1 + C2; 88% C3; 83% C4; 78% pooled placebo) . Most AEs were of mild severity, drug-related for RGT-075 groups, and predominantly GI with no serious AEs or deaths. Baseline HbA1c was highly variable (7.2-9.0%) ; HbA1c mean changes from baseline ranged -0.6 to -1.2% across RGT-075 doses vs. -0.37% with placebo and correlated with FPG, CGM-TIR and MMTT results. BW mean change ranged -2.3 to -4.5 kg across RGT-075 doses vs -1.1 kg with placebo. RGT-075 plasma exposures increased as the dose levels increased.

Conclusion: RGT-075 GLP1RA oral small molecule (15-180 mg/day) up to 28 days was safe and QD dosing showed promising exploratory efficacy trends despite high baseline variability and short treatment duration.

Disclosure

M. A. Pirner: Employee; Regor Pharmaceuticals, Inc. J. Lin: None. F. Liu: Employee; Regor Pharmaceuticals Inc. L. Yao: None. M. E. Zettler: Employee; Cardinal Health, Regor Pharmaceuticals Inc. D. J. Valacer: Employee; Regor Pharmaceuticals, Inc.
960-P: Multisite Quality Improvement Initiative within the Project ECHO Diabetes Virtual Network
Authors: WANG C JASON , LEWIT EUGENE , CLARK CATHERINE , MAAHS DAVID M. , HALLER MICHAEL J. , ADDALA ANANTA , LAL RAYHAN , CUTTRISS NICOLAS , BAER LINDA G. , FIGG LAUREN , ANEZ-ZABALA CLAUDIA , SHEEHAN ELENI , WESTEN SARAH C. , DEREMER CHRISTINA E. , BERNIER ANGELINA , DONAHOO WILLIAM T. , WALKER ASHBY F.
Published: May 2022

Poor outcomes for people with diabetes have necessitated targeted quality improvement (QI) projects to affect change. Project ECHO Diabetes is a tele-education and tele-mentoring program for community health clinics in California and Florida serving under-resourced patients with diabetes who lack routine access to specialty care. The model provided a unique opportunity to undertake a multi-site QI initiative, where 12 community clinics participated in measuring and improving quality of care. Using a modified-Delphi approach, clinic providers rated various QI measures on their validity and feasibility. A total of 18 measures were selected, and each clinic chose its own measures to track throughout the one-year initiative. The number of measures each clinic focused on ranged from 1 to 9, with a median of 3. Quarterly, clinics met remotely to report performance based on selected measures and discuss their efforts, successes, and setbacks. At the end of the QI year, clinics reported widespread improvements across structural, process, and outcome measures (Table) . Remarkable improvement ideas came from the sharing of best practices during the remote tele-ECHO clinic sessions and the changes made in the data systems used to track important measures. The Project ECHO Diabetes tele-education model has the potential to improve care for people living with diabetes in clinics serving under-resourced communities.

Disclosure

C.Wang: None. L.Figg: None. C.Anez-zabala: None. E.Sheehan: None. S.C.Westen: None. C.E.Deremer: Research Support; Pfizer-BMS Alliance, Stock/Shareholder; Portola Pharmaceuticals, Inc. A.Bernier: None. W.T.Donahoo: None. A.F.Walker: None. E.Lewit: n/a. C.Clark: None. D.M.Maahs: Advisory Panel; Abbott Diabetes, Eli Lilly and Company, Medtronic, Novo Nordisk, Sanofi, Consultant; Aditx Therapeutics, Inc., Biospex. M.J.Haller: Advisory Panel; SAB Biotherapeutics , Consultant; MannKind Corporation, Sanofi. A.Addala: None. R.Lal: Advisory Panel; Provention Bio, Inc., Consultant; Abbott Diabetes, Biolinq, Capillary Biomedical, Inc., Deep Valley Labs, Gluroo, Morgan Stanley, Tidepool. N.Cuttriss: Advisory Panel; American Diabetes Association, Board Member; American Youth Understanding Diabetes Abroad , Consultant; Cecelia Health, Leona M. and Harry B. Helmsley Charitable Trust, Med-IQ. L.G.Baer: None.

Funding

The Leona M. and Harry B. Helmsley Charitable Trust
997-P: TG/HDL Ratio as a Predictor of Insulin Resistance in U.S. Adolescents: Do Age and Sex Percentiles Matter?
Authors: ENG DONNA , GREGG BRIGID , SINGER KANAKADURGA , LEE JOYCE M.
Published: May 2022

Identifying children with insulin resistance (IR) is difficult due to insulin assay reliability/reproducibility. We examined if the triglyceride/high-density lipoprotein ratio (TG/HDL) can identify children with IR and if it is important to use age- & sex-specific cutoffs. In a representative sample of 3,464 US adolescents 12-18 yrs participating in NHANES (2003-2020) , we calculated the fasting TG/HDL ratio & homeostasis model assessment-insulin resistance level (HOMA-IR) . We established age- & sex-specific & universal percentiles (10th, 25th, 50th, 75th, 95th) for TG/HDL ratio based on a subset of normal weight adolescents; IR was defined as having a HOMA-IR >4.39. We created receiver operating characteristic (ROC) curves predicting IR comparing age- & sex-specific, universal TG/HDL ratios, and raw TG/HDL cutpoints. Half were female, 14% were black, 13% were Mexican-American, and 24% had IR. AUC was similar for age-,sex-specific (0.69 (SE 0.01)) , universal (0.69 (SE 0.01)) percentiles and raw TG/HDL ratios (0.69 (SE 0.01)) (p=0.22) . Age and sex cutoffs did not provide further discrimination for identifying adolescents with IR. A universal TG/HDL ratio cutoff of 1.0 conferred a sensitivity of 84% and specificity of 42%. A TG/HDL ratio of 1.0 may be a reasonable test cutoff for identifying adolescents with IR, given that higher detection rates may improve identification of high risk children.

Disclosure

D.Eng: None. B.Gregg: None. K.Singer: None. J.M.Lee: Advisory Panel; GoodRx, Consultant; Tandem Diabetes Care, Inc.

Funding

Caswell Diabetes Institute at the University of Michigan
Program Cash For Work (CFW) Sebagai Upaya Pemerintah dalam Mitigasi Pandemi Covid-19 (Studi Pada Kelurahan Kebonsari Wetan Kecamatan Kanigaran Kota Probolinggo)
Authors:   Universitas Panca Marga, Marwiyah Siti , Rahmadi Andhi ,   Universitas Panca Marga, Aisyah Riza ,   Universitas Panca Marga
Published: May 2022

The issue of layoffs is currently an important issue in the employment sector, marked by a significant increase in the unemployment rate due to the COVID-19 pandemic. Various strategies and policies were issued by the Indonesian government to push back the pace of the community's economy through the cash for work program launched by the Ministry of Public Works and Public Housing during the COVID-19 pandemic. The form of mitigation carried out between natural and non-natural disasters is certainly different, seeing the phenomena that are happening, the Indonesian government should take mitigation efforts. This paper intends to examine the effectiveness of the cash for work program during the COVID-19 pandemic in the Kebonsari Wetan Village, Kanigaran District, Probolinggo City, which is one of the villages that has the opportunity to implement the cash for work program. This study used descriptive qualitative method. The selection of informants was chosen deliberately who was considered to understand the matter to be studied, took data from sources that were considered relevant according to the problems and themes raised, so as to produce reliable data and determine the accuracy of the research results. Based on the results of interviews and field studies, it was found that the implementation of the cash for work program during the covid-19 pandemic in Kebonsari Wetan Village had carried out activities and implemented principles in accordance with standard operating procedures (POS) and the cash for work program in infrastructure activities was running effectively. and easy to do by reviewing effectiveness according to Sutrisno (in Wulandari 2018:6) namely program understanding, timeliness, target accuracy, goal achievement and real change